Background: Both propofol and volatile anesthetics have been reported to interact with the endocannabinoid system. The purpose of this study was to evaluate the effect of selective agonists for cannabinoid receptor types 1 and 2 on etomidateinduced sedation.
ENDOCANNABINOIDS have been demonstrated to play an important role in the physiologic control of sleep, sedation, anxiety, pain processing, and emesis, suggesting a possible role as adjuvants during anesthesia. 1 The endocannabinoid system includes two identified cannabinoid receptors: type 1, which mainly exists in the central nervous system, and type 2, which is absent from the brain but is enriched in peripheral neuronal and immune tissues. 2 It has recently been proposed that the anesthetic drug propofol induces an increase in the brain content of the endocannabinoid anandamide and that this may contribute to the sedative effects of propofol. 3 Furthermore, volatile anesthetic-evoked sleep duration has been reported to be prolonged by different exogenously administered cannabinoids. 4 Etomidate (R-(ϩ)ethyl-1-(1-phenylethyl)-1H-imidazole-5-carboxylate) is a widely used potent hypnotic drug whose major advantage has been described as hemodynamic stability. This pharmacologic profile renders etomidate particularly suitable for induction of anesthesia in critically ill patients and patients with cardiovascular disease. 5 The anesthetic effect is thought to be mediated primarily through an action on ␥-aminobutyric acid receptors. 6 In addition, interactions of etomidate with ␣ 2 adrenoreceptors 7 and the nitric oxide metabolism 8 have been suggested.
To elucidate the role of cannabinoid receptors in the anesthetic action of etomidate, we studied the interaction of etomidate with selective agonists and antagonists for cannabinoid 1/2 receptors in vivo in mice. We hypothesized that the activation of the cannabinoid 1 receptor increases etomidate-induced sedation, but not activation of the cannabinoid 2 receptor.
Materials and Methods

Animals
This project was approved by the Animal Investigation
Committee of the University Schleswig-Holstein, Campus Kiel, Germany, and the animals were managed in accordance with institutional guidelines. This was a controlled, blinded, randomized, experimental study in 20 mice (129S2/SVHsd) of either sex, weighing 25-35 g. Mice were housed 4 animals per cage and maintained on a 12-h light-dark cycle with free access to water and food. All experiments were conducted between 08:00 and 18:00 h.
A total of 20 mice were used in this study. Each following drug combination was applied to 6 -8 mice of these 20 study animals. Thus, each animal was repeatedly exposed to different drug combinations. To avoid any interference with drug remnants from the previous regimen, a washout period of at least 20 days was chosen. , and saline in a 1:1:18 ratio. Solvents were also used as vehicle control for cannabinoid 1/2 receptor agonists and antagonists, respectively. All drugs were administered intraperitoneally in a volume of 10 ml/kg body weight, and animals were weighed on the day of the experiment for calculation.
Drugs
Sedation
Sedation was determined by placing mice on a rotating wheel (Rota-Rod; Ugo Basile, Comerio, Italy), and measuring the duration of time they remained on the rod as described previously. 7 Mice were initially trained until they could stay on the Rota-Rod for at least 60 s at a speed of 28 revolutions per minute. Time on the RotaRod was recorded 1, 2.5, 5, 7.5, 10, 15, 20, 30, 45, 60, 75, and 90 min after drug administration. The observer was blinded with respect to the drugs applied. 
Agonists and Etomidate
Statistical Analysis
Statistics were performed using commercially available statistics software (GraphPad Prism version 4.03 for Windows; GraphPad Software, San Diego, CA). A Kolmogorov-Smirnov test was used to test for gaussian distribution. Data were analyzed using two-way repeatedmeasures analysis of variance factoring for time and drug effects with post hoc Bonferroni correction. Data are expressed as mean Ϯ SEM. The dose-response lines were fitted using least-squares linear regression and ED 50 . Drug combinations were analyzed for additive interactions using a "fixed ratio design" isobologram whereby combinations of two drugs in known ratios were administered as fractions of their respective ED 50 , as outlined above. 13 The isobologram consists of an additivity line that connects the ED 50 of ACEA on the vertical axis to the ED 50 of etomidate on the horizontal axis. The theoretical dose required for a purely additive interaction (Z add ϭ (f)ED 50 , drug A ϩ (1 Ϫ f)ED 50, drug B , where f is the fraction of drug A used) was calculated and compared via an unpaired Student t test to the actual dose (Z mix , determined from the ED 50 of the combination doseresponse curve) required to achieve the same effect experimentally. Statistical significance was considered at a twosided P value of less than 0.05. 
Results
Single
Discussion
Etomidate is widely used for induction of anesthesia, particularly in critically ill patients, because of its beneficial properties, including rapid, predictable onset of action, cardiovascular stability, and short half-life. 5 In agreement with previous experimental studies, 14, 15 intraperitoneal injection of etomidate reduced time on the Rota-Rod, an index of the sedative action of general anesthetics in mice, in a dose-dependent manner.
Main findings of our experimental study in mice are as follows. First, etomidate and the cannabinoid 1 receptor agonist ACEA alone reduced time on the Rota-Rod in a dose-dependent manner, indicating increased sedation, whereas the cannabinoid 2 receptor agonist JWH 133 had no effect, irrespective of the dosage used. Second, etomidate-induced sedation was significantly increased and prolonged with ACEA, but not with JWH 133. However, isobolographic analysis revealed that this interaction is based on simple additivity. Third, the anesthetic action of etomidate is not mediated via cannabinoid receptors.
With regard to natural cannabinoids, their analgesic and sedative properties have historically been used during surgical procedures more than three centuries ago. 16 In our experimental study, the synthetic cannabinoid 1 receptor agonist ACEA altered the Rota-Rod performance by decreasing time on the Rota-Rod in a dosedependent manner, whereas the cannabinoid 2 receptor agonist JWH 133 had no effect. Cannabinoid 1 receptors are located throughout the central nervous system, including the neocortex, hippocampus, basal ganglia, and brainstem, 17 regions that have been associated with sedation. 18 In this respect, sleep duration of volatile anesthetics such as halothane or isoflurane has been reported to be prolonged when combined with both nonselective and selective cannabinoid 1 receptor agonists. 4 Delta-9- Tetrahydrocannabinol enhanced thiopental-induced loss of righting reflex, too. 19 In addition, propofol-evoked loss of righting reflex was increased by coadministration of a nonselective cannabinoid 1 receptor agonist. 3 These authors have further suggested that propofol induces an inhibition of the anandamide-degrading enzyme, the fatty acid amide hydrolase that leads to elevated concentration of anandamide, an endogenous nonselective cannabinoid 1/2 receptor ligand, which in turn may contribute to the sedative effects of propofol. More recently, even a reduced anandamide concentration has been reported after etomidate administration in patients, suggesting counteracting effects of etomidate and fatty acid amide hydrolase. 20 The current study indicates that activation of the cannabinoid 1 receptor by ACEA increased and prolonged significantly etomidate-induced sedation, suggesting a potentially anesthetic-sparing effect. Furthermore, isobolographic analysis of this study revealed that our results for the combination of ACEA and etomidate represent a simple additive interaction, suggesting that activation of both cannabinoid receptors and ␥-aminobutyric acid receptors cause sedation by independent mechanisms or sites of action. However, the fact that lower doses of sedative drugs may be administered in combination to cause effective sedation may have potential clinical benefit. Additive drug combinations may enhance the pharmacodynamic safety margin because the lower clinical dose requirements for each agent will minimize drugspecific adverse effects. 21 In addition, as etomidate is not used for repetitive administration and long-term sedation because of its detrimental effect on adrenal function, 22 enhanced and prolonged sedative effects after a single etomidate injection might be advantageous under special circumstances.
With respect to an appropriate effect size for the difference between the actually measured additive dose, Z mix , and the theoretical one, Z add , we considered a difference of 10% or greater between the observed and expected absolute dose in mg/kg of etomidate or ACEA to be clinically meaningful. At none of the four different fractional ED 50 levels did we obtain any such difference. Hence, not only did the Student t test give a nonsignificant result, but also the mean data differed by less than the clinically relevant effect size. Therefore, it can reasonably concluded that the interaction is simply additive.
Furthermore, a pharmacokinetic alteration of the endocannabinoid system by etomidate 3 is unlikely because an inhibition of fatty acid amide hydrolase by etomidate has not yet been demonstrated, and ACEA metabolism is independent of fatty acid amide hydrolase. 23 Moreover, an interaction between ACEA and the lipid solvent contained in the etomidate emulsion also seems highly improbable, because the combination of both drugs did not affect Rota-Rod performance. In addition, although etomidate is indeed known as an inhibitor of cytochrome P450 3A4, ACEA has, to the best of our knowledge, not been reported as a substrate, inhibitor, or inducer of any CYP isoenzyme including CYP3A4. Hence, CYP-mediated drug-drug interactions are also unlikely. However, it remains speculative whether other interactions between ACEA and etomidate, especially given by the intraperitoneal route, may have influenced the results obtained.
In terms of pretreatment of mice with the cannabinoid 1 receptor antagonist AM 251 that did not significantly change etomidate-induced sedation, sedative properties of etomidate may not depend on activation of cannabinoid 1/2 receptors by endocannabinoids per se, whereas an endogenous cannabinoid tone mediated by cannabinoid 1 receptors has been suggested to contribute to sedative-hypnotic effects of propofol. 3 To further determine whether the effects of cannabinoids were mediated through certain subtypes of cannabinoid receptors, the cannabinoid 1 receptor antagonist AM 251 and cannabinoid 2 receptor antagonist AM 630 were administered 10 min before the delivery of ACEA and JWH 133, respectively. Therefore, AM 251 reversed the sedative component of ACEA when ACEA was administered both alone and in combination with etomidate. In contrast to cannabinoid 1 receptor activation, the cannabinoid 2 receptor agonist JWH 133 did not affect etomidate-induced Rota-Rod performance. This difference is not astonishing, because cannabinoid 2 receptors have been demonstrated to be predominantly expressed in peripheral neuronal tissue and in the immune system, 2 and single cannabinoid 2 receptor activation did not induce impairment in motor coordination in our study.
Several limitations to this study should be noted. First, the use of the intraperitoneal route enables hepatic metabolism, and we did not determine serum concentration or brain content of the drugs applied and their active metabolites. Second, we did not perform any ligandbinding studies to elucidate a direct activation of cannabinoid 1 receptors by etomidate. Third, effects of drugs given throughout the study on systemic hemodynamic and respiratory variables were not evaluated. Further, both the timing and the dose of the cannabinoid 1 receptor antagonist used may be responsible for the negative effect on etomidate-induced sedation. However, 5 mg/kg AM 251 reversed the sedative effect of single drug administration of ACEA completely. Therefore, the dose range of AM 251 used in our study may provide sufficient antagonistic properties at the cannabinoid 1 receptor when combined with etomidate. With respect to effect site concentrations, in the clinical context, dosing of anesthetic drugs is usually accomplished irrespective of plasma concentrations. Hence, our results are particularly meaningful because they translate from dose to response as opposed to concentration to response. Finally, data from animals should be extrapolated to humans with caution.
In conclusion, activation of the cannabinoid 1 receptor, but not of the cannabinoid 2 receptor, resulted in increased and prolonged etomidate-evoked sedation based on an additive interaction. Therefore, these data suggest that selective cannabinoid 1 receptor agonists could be novel targets for anesthetic drug development.
